Following a thorough review of available data, AbbVie shall not exercise its to in-permit the Galapagos JAK1 inhibitor, filgotinib. ‘We believe ABT-494 gets the potential to become best-in-class therapy for individuals,’ said Michael Severino, M.D., executive vice president, development and research and chief scientific officer, AbbVie. ‘Inside our view, ABT-494 also offers a faster path to Phase 3 advancement with much less uncertainty.’ Per the conditions of the contract with Galapagos, all privileges to filgotinib will revert exclusively to Galapagos..Ray Suarez discusses what’s behind these changes with Susan Dentzer of Health Affairs .S. Health care spending this year 2010 grew at the second-slowest rate in 51 years, as patients continued to postpone hospitalizations, fill up fewer drug prescriptions and steer clear of doctor appointments in the aftermath of the fantastic Recession, according to a government report released Monday. Medscape: Spending on Physician Solutions Continues to DECELERATE One of the most dramatic deacclerations was seen in prescription drugs, where spending development proceeded to go from 5. The authors chalked up this near-plateau in expenditures to the raising use of generic drugs, the loss of patent protection for certain brand-name drugs, fewer brand-new drugs producing their debut, and slower development in the quantity of medications consumed.